{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T14:17:33Z","timestamp":1779891453942,"version":"3.53.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Musculoskelet Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Bisphosphonates and denosumab can increase bone mineral density (BMD) and are used to treat osteoporosis caused by aromatase inhibitors (AIs). However, few studies have been conducted on the effects of both on vertebral compression fractures (VCFs). This article aims to compare the effects of alendronate sodium and denosumab injection on the frequency of VCFs in postmenopausal women whose osteoporosis was brought on by AIs treatment for breast cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort study was conducted from January 2020 to December 2024, enrolling 121eligible breast cancer patients with aromatase inhibitor-associated osteoporosis from the orthopedic outpatient department of Foshan Hospital of Traditional Chinese Medicine. Patients were divided into two treatment groups: the alendronate group received oral alendronate sodium tablets (70\u00a0mg once weekly), while the denosumab group received subcutaneous denosumab injections (60\u00a0mg every 6 months). Both groups were supplemented with calcitriol and calcium carbonate\/vitamin D3 tablets as baseline therapy. The observation period was 12 months. The following parameters were compared between the two groups before and after treatment: BMD, 25-hydroxy Vitamin D3 (25-OH D3), \u03b2-C-terminal telopeptide of type I collagen (\u03b2-CTX) and Procollagen I N-Terminal Propeptide (PINP), Visual Analog Scale (VAS) scores and Incidence of VCFs. Statistical analysis was performed using SPSS 27.0.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The study included a total of 121 patients. Post-treatment analysis revealed a significantly higher overall response rate in the denosumab group(\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200957) (91.22%) compared to the alendronate group(\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200964) (82.81%;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05). Notably, the denosumab group demonstrated superior outcomes in the following two areas: (1) significantly greater improvement in BMD, (2) lower incidence of vertebral compression fractures (both\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05). Both treatment groups showed statistically significant improvements in bone metabolism markers following treatment (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Both therapeutic regimens effectively improved BMD in the study population. However, comparative analysis revealed that denosumab injection (60\u00a0mg every 6 months) demonstrated significant advantages over weekly alendronate sodium (70\u00a0mg) in multiple clinical outcomes. Specifically, the denosumab group showed: (1) greater BMD improvement at all measured skeletal sites, and (2) a significantly lower incidence of VCFs (all\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05) in postmenopausal women with aromatase inhibitor-associated osteoporosis.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12891-025-09280-w","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T15:50:31Z","timestamp":1762962631000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of denosumab versus alendronate for aromatase inhibitor-associated osteoporosis in postmenopausal breast cancer patients: a retrospective analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Yi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhe","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"issue":"4","key":"9280_CR1","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1038\/s41591-025-03502-3","volume":"31","author":"J Kim","year":"2025","unstructured":"Kim J, Harper A, McCormack V, et al. Global patterns and trends in breast cancer incidence and mortality across 185 countries. Nat Med. 2025;31(4):1154\u201362.","journal-title":"Nat Med"},{"issue":"12","key":"9280_CR2","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.3390\/cells9122644","volume":"9","author":"E Zattarin","year":"2020","unstructured":"Zattarin E, Leporati R, Ligorio F, et al. Hormone receptor loss in breast cancer: molecular Mechanisms, clinical Settings, and therapeutic implications. Cells. 2020;9(12):2644. Published 2020 Dec 9.","journal-title":"Cells"},{"issue":"41","key":"9280_CR3","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000039961","volume":"103","author":"L Chen","year":"2024","unstructured":"Chen L, Zhang Y, Li J, Kalmar A. Efficacy and safety of traditional Chinese medicine in managing bone loss post-endocrine therapy in hormone receptor-positive breast cancer patients. Medicine (Baltimore). 2024;103(41):e39961.","journal-title":"Medicine (Baltimore)"},{"issue":"13","key":"9280_CR4","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1200\/JCO.20.03399","volume":"39","author":"LA Korde","year":"2021","unstructured":"Korde LA, Somerfield MR, Carey LA, et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. J Clin Oncol. 2021;39(13):1485\u2013505.","journal-title":"J Clin Oncol"},{"key":"9280_CR5","doi-asserted-by":"publisher","first-page":"1218206","DOI":"10.3389\/fonc.2023.1218206","volume":"13","author":"J Xu","year":"2023","unstructured":"Xu J, Cao B, Li C, Li G. The recent progress of endocrine therapy-induced osteoporosis in estrogen-positive breast cancer therapy. Front Oncol. 2023;13:1218206. Published 2023 Jul 7.","journal-title":"Front Oncol"},{"key":"9280_CR6","doi-asserted-by":"publisher","first-page":"100355","DOI":"10.1016\/j.jbo.2021.100355","volume":"28","author":"K Waqas","year":"2021","unstructured":"Waqas K, Lima Ferreira J, Tsourdi E, Body JJ, Hadji P, Zillikens MC. Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer. J Bone Oncol. 2021;28:100355. Published 2021 Mar 18.","journal-title":"J Bone Oncol"},{"issue":"12","key":"9280_CR7","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1007\/s40279-022-01733-9","volume":"52","author":"A Pellegrino","year":"2022","unstructured":"Pellegrino A, Tiidus PM, Vandenboom R. Mechanisms of estrogen influence on skeletal muscle: mass, regeneration, and mitochondrial function. Sports Med. 2022;52(12):2853\u201369.","journal-title":"Sports Med"},{"key":"9280_CR8","doi-asserted-by":"publisher","first-page":"1437061","DOI":"10.1155\/2022\/1437061","volume":"2022","author":"AB Roomi","year":"2022","unstructured":"Roomi AB, Mahdi Salih AH, Noori SD, Nori W, Tariq S. Evaluation of bone mineral Density, serum Osteocalcin, and osteopontin levels in postmenopausal women with type 2 diabetes Mellitus, with\/without osteoporosis. J Osteoporos. 2022;2022:1437061. Published 2022 Feb 14.","journal-title":"J Osteoporos"},{"key":"9280_CR9","doi-asserted-by":"publisher","first-page":"5325813","DOI":"10.1155\/2021\/5325813","volume":"2021","author":"AB Roomi","year":"2021","unstructured":"Roomi AB, Nori W, Al-Badry SH. The value of serum adiponectin in osteoporotic women: does weight have an effect? J Obes. 2021;2021:5325813. Published 2021 Nov 9.","journal-title":"J Obes"},{"issue":"2","key":"9280_CR10","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00774-018-0917-0","volume":"37","author":"K Nakatsukasa","year":"2019","unstructured":"Nakatsukasa K, Koyama H, Ouchi Y, et al. Effects of denosumab on bone mineral density in Japanese women with osteoporosis treated with aromatase inhibitors for breast cancer. J Bone Miner Metab. 2019;37(2):301\u20136.","journal-title":"J Bone Miner Metab"},{"issue":"7","key":"9280_CR11","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0025-6196(11)60752-0","volume":"84","author":"KA Kennel","year":"2009","unstructured":"Kennel KA, Drake MT. Adverse effects of bisphosphonates: implications for osteoporosis management. Mayo Clin Proc. 2009;84(7):632\u20138.","journal-title":"Mayo Clin Proc"},{"issue":"11","key":"9280_CR12","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1038\/s41416-018-0225-4","volume":"119","author":"V Giannakeas","year":"2018","unstructured":"Giannakeas V, Cadarette SM, Ban JK, Lipscombe L, Narod SA, Kotsopoulos J. Denosumab and breast cancer risk in postmenopausal women: a population-based cohort study. Br J Cancer. 2018;119(11):1421\u20137.","journal-title":"Br J Cancer"},{"issue":"11","key":"9280_CR13","first-page":"1189","volume":"56","author":"W Wang","year":"2021","unstructured":"Wang W. Effects and progress of anti-osteoporosis drugs [J]. Chin J Med. 2021;56(11):1189\u201392.","journal-title":"Chin J Med"},{"issue":"03","key":"9280_CR14","first-page":"317","volume":"36","author":"L Jian","year":"2023","unstructured":"Jian L, Dongwen L, Da L, et al. Research progress on Zoledronic acid versus denosumab in the treatment of primary osteoporosis [J]. Med Res Trauma Treat. 2023;36(03):317\u201323.","journal-title":"Med Res Trauma Treat"},{"key":"9280_CR15","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1007\/s00198-014-3023-8","volume":"26","author":"AM Burden","year":"2015","unstructured":"Burden AM, Tadrous M, Calzavara A, Cadarette SM. Uptake and characteristics of Zoledronic acid and denosumab patients and physicians in Ontario, Canada: impact of drug formulary access. Osteoporos Int. 2015;26:1525\u201333.","journal-title":"Osteoporos Int"},{"issue":"04","key":"9280_CR16","first-page":"256","volume":"12","author":"M Dandan","year":"2018","unstructured":"Dandan M, Dan Z. Update of the American society of clinical oncology clinical practice guidelines for adjuvant chemotherapy and targeted therapy in early breast cancer (2018 Edition) [J]. Chin J Breast Disease (Electronic Edition). 2018;12(04):256.","journal-title":"Chin J Breast Disease (Electronic Edition)"},{"issue":"03","key":"9280_CR17","first-page":"385","volume":"5","author":"S Li","year":"2011","unstructured":"Li S, Xiaowei Q. Guidelines from the American society of clinical oncology and the college of American pathologists for immunohistochemical detection of Estrogen\/Progesterone receptors in breast cancer [J]. Chin J Breast Disease (Electronic Edition). 2011;5(03):385\u20137.","journal-title":"Chin J Breast Disease (Electronic Edition)"},{"issue":"4","key":"9280_CR18","first-page":"289","volume":"30","author":"YH Zhang Zhenlin","year":"2024","unstructured":"Zhang Zhenlin YH. Key points analysis of the guidelines for the diagnosis and treatment of primary osteoporosis (2022 Edition) [J]. J Intern Crit Care. 2024;30(4):289\u201393.","journal-title":"J Intern Crit Care"},{"issue":"1","key":"9280_CR19","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s10549-019-05518-z","volume":"180","author":"S Yao","year":"2020","unstructured":"Yao S, Laurent CA, Roh JM, et al. Serum bone markers and risk of osteoporosis and fragility fractures in women who received endocrine therapy for breast cancer: a prospective study. Breast Cancer Res Treat. 2020;180(1):187\u201395.","journal-title":"Breast Cancer Res Treat"},{"issue":"10001","key":"9280_CR20","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","volume":"386","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2015","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386(10001):1341\u201352.","journal-title":"Lancet"},{"key":"9280_CR21","unstructured":"Davies C, Pan H, Godwin J et al. Long-term effects of continuing adjuvant Tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial [published correction appears in lancet. 2013;381(9869):804."},{"key":"9280_CR22","doi-asserted-by":"publisher","first-page":"5594542","DOI":"10.1155\/2024\/5594542","volume":"2024","author":"B Goel","year":"2024","unstructured":"Goel B, Virmani T, Jain V, Kumar G, Sharma A, Al Noman A. Unveiling the link between breast cancer treatment and osteoporosis: implications for anticancer therapy and bone health. Biomed Res Int. 2024;2024:5594542. Published 2024 Nov 14.","journal-title":"Biomed Res Int"},{"issue":"8","key":"9280_CR23","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1002\/acr.23121","volume":"69","author":"LA Deveza","year":"2017","unstructured":"Deveza LA, Kraus VB, Collins JE, et al. Association between biochemical markers of bone turnover and bone changes on imaging: data from the osteoarthritis initiative. Arthritis Care Res (Hoboken). 2017;69(8):1179\u201391.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"9280_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx141","author":"H Goldvaser","year":"2018","unstructured":"Goldvaser H, Barnes TA, \u0160eruga B, et al. Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst. 2018. https:\/\/doi.org\/10.1093\/jnci\/djx141.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"9280_CR25","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1604700","volume":"375","author":"PE Goss","year":"2016","unstructured":"Goss PE, Ingle JN, Pritchard KI, et al. Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med. 2016;375(3):209\u201319.","journal-title":"N Engl J Med"},{"issue":"6","key":"9280_CR26","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s00774-021-01239-w","volume":"39","author":"S Kuba","year":"2021","unstructured":"Kuba S, Watanabe K, Chiba K, et al. Adjuvant endocrine therapy effects on bone mineral density and microstructure in women with breast cancer. J Bone Miner Metab. 2021;39(6):1031\u201340.","journal-title":"J Bone Miner Metab"},{"issue":"4","key":"9280_CR27","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1159\/000523695","volume":"17","author":"S Chen","year":"2022","unstructured":"Chen S, Bo L, Lv D, Ma F. Bone safety profile of steroidal aromatase inhibitor in comparison to nonsteroidal aromatase inhibitors in postmenopausal women with breast cancer: a network meta-analysis. Breast Care. 2022;17(4):391\u2013402.","journal-title":"Breast Care"},{"issue":"5","key":"9280_CR28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11864-021-00835-2","volume":"22","author":"A Diana","year":"2021","unstructured":"Diana A, Carlino F, Giunta EF, et al. Cancer Treatment-Induced bone loss (CTIBL): state of the Art and proper management in breast cancer patients on endocrine therapy. Curr Treat Options Oncol. 2021;22(5):45. Published 2021 Apr 16.","journal-title":"Curr Treat Options Oncol"},{"issue":"4","key":"9280_CR29","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00198-023-06683-0","volume":"34","author":"B Mugnier","year":"2023","unstructured":"Mugnier B, Goncalves A, Daumas A, et al. Prevention of aromatase inhibitor-induced bone loss with anti-resorptive therapy in post-menopausal women with early-stage breast cancer. Osteoporos Int. 2023;34(4):703\u201311.","journal-title":"Osteoporos Int"},{"issue":"2","key":"9280_CR30","doi-asserted-by":"publisher","first-page":"182","DOI":"10.7326\/M22-0684","volume":"176","author":"C Ayers","year":"2023","unstructured":"Ayers C, Kansagara D, Lazur B, Fu R, Kwon A, Harrod C. Effectiveness and safety of treatments to prevent fractures in people with low bone mass or primary osteoporosis: a living systematic review and network meta-analysis for the American college of physicians [published correction appears in ann intern Med. 2023;176(6):884. doi: 10.7326\/L23-0105]. Ann Intern Med. 2023;176(2):182\u201395.","journal-title":"Ann Intern Med"},{"issue":"04","key":"9280_CR31","first-page":"241","volume":"30","author":"Chinese Gerontological Health Medicine Research Association, Geriatric Pain Diseases Branch","year":"2024","unstructured":"Chinese Gerontological Health Medicine Research Association, Geriatric Pain Diseases Branch. Chinese expert consensus on Diagnosis, treatment and management of geriatric osteoporotic pain (2024 Edition) [J]. Chin J Pain Med. 2024;30(04):241\u201350.","journal-title":"Chin J Pain Med"},{"issue":"10","key":"9280_CR32","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1177\/1060028018768808","volume":"52","author":"P Morizio","year":"2018","unstructured":"Morizio P, Burkhart JI, Ozawa S, Denosumab. A unique perspective on adherence and Cost-effectiveness compared with oral bisphosphonates in osteoporosis patients. Ann Pharmacother. 2018;52(10):1031\u201341.","journal-title":"Ann Pharmacother"},{"issue":"8","key":"9280_CR33","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1007\/s00198-024-07118-0","volume":"35","author":"T obayashi","year":"2024","unstructured":"obayashi T, Morimoto T, Ito K, Mawatari M, Shimazaki T. Denosumab vs. bisphosphonates in primary osteoporosis: a meta-analysis of comparative safety in randomized controlled trials. Osteoporos Int. 2024;35(8):1377\u201393.","journal-title":"Osteoporos Int"},{"issue":"3","key":"9280_CR34","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00774-023-01408-z","volume":"41","author":"T Ishikawa","year":"2023","unstructured":"Ishikawa T. Differences between zoledronic acid and denosumab for breast cancer treatment. J Bone Miner Metab. 2023;41(3):301\u20136.","journal-title":"J Bone Miner Metab"},{"key":"9280_CR35","doi-asserted-by":"publisher","first-page":"100252","DOI":"10.1016\/j.jbo.2019.100252","volume":"18","author":"A Galvano","year":"2019","unstructured":"Galvano A, Scaturro D, Badalamenti G, et al. Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials. J Bone Oncol. 2019;18:100252. Published 2019 Jul 16.","journal-title":"J Bone Oncol"},{"key":"9280_CR36","doi-asserted-by":"publisher","first-page":"e068033","DOI":"10.1136\/bmj-2021-068033","volume":"381","author":"MN H\u00e4ndel","year":"2023","unstructured":"H\u00e4ndel MN, Cardoso I, von B\u00fclow C, et al. Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials. BMJ. 2023;381:e068033. Published 2023 May 2.","journal-title":"BMJ"},{"issue":"9992","key":"9280_CR37","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","volume":"386","author":"M Gnant","year":"2015","unstructured":"Gnant M, Pfeiler G, Dubsky PC, et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015;386(9992):433\u201343.","journal-title":"Lancet"},{"issue":"1","key":"9280_CR38","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s11657-023-01211-3","volume":"18","author":"K Nicolopoulos","year":"2023","unstructured":"Nicolopoulos K, Moshi MR, Stringer D, Ma N, Jenal M, Vreugdenburg T. The clinical effectiveness of denosumab (Prolia\u00ae) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective Estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis. Arch Osteoporos. 2023;18(1):18. Published 2023 Jan 10.","journal-title":"Arch Osteoporos"},{"issue":"9","key":"9280_CR39","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1080\/14740338.2024.2386365","volume":"23","author":"DL Diab","year":"2024","unstructured":"Diab DL, Watts NB. The use of denosumab in osteoporosis - an update on efficacy and drug safety. Expert Opin Drug Saf. 2024;23(9):1069\u201377.","journal-title":"Expert Opin Drug Saf"},{"issue":"8","key":"9280_CR40","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1007\/s00198-024-07118-0","volume":"35","author":"T Kobayashi","year":"2024","unstructured":"Kobayashi T, Morimoto T, Ito K, Mawatari M, Shimazaki T. Denosumab vs. bisphosphonates in primary osteoporosis: a meta-analysis of comparative safety in randomized controlled trials. Osteoporos Int. 2024;35(8):1377\u201393.","journal-title":"Osteoporos Int"},{"issue":"1","key":"9280_CR41","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3390\/nu15010094","volume":"15","author":"B Wang","year":"2022","unstructured":"Wang B, Cheng X, Fu S, et al. Associations of serum 25(OH)D, PTH, and \u03b2-CTX levels with All-Cause mortality in Chinese Community-Dwelling centenarians. Nutrients. 2022;15(1):94. Published 2022 Dec 24.","journal-title":"Nutrients"},{"issue":"22","key":"9280_CR42","doi-asserted-by":"publisher","first-page":"12292","DOI":"10.3390\/ijms222212292","volume":"22","author":"ER Scheidemann","year":"2021","unstructured":"Scheidemann ER, Shajahan-Haq AN. Resistance to CDK4\/6 inhibitors in Estrogen Receptor-Positive breast cancer. Int J Mol Sci. 2021;22(22):12292. Published 2021 Nov 14.","journal-title":"Int J Mol Sci"}],"container-title":["BMC Musculoskeletal Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-025-09280-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12891-025-09280-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-025-09280-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T15:50:33Z","timestamp":1762962633000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmusculoskeletdisord.biomedcentral.com\/articles\/10.1186\/s12891-025-09280-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9280"],"URL":"https:\/\/doi.org\/10.1186\/s12891-025-09280-w","relation":{},"ISSN":["1471-2474"],"issn-type":[{"value":"1471-2474","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]},"assertion":[{"value":"4 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the Ethics Committee of Foshan Hospital of Traditional Chinese Medicine (No. KY2025198) and all methods were conducted in accordance with the guidelines of the Declaration of Helsinki. All the patients consented to participate in this study, and informed consents were signed by themselves.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1040"}}